Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.87
-0.2400-1.83%
Post-market: 12.870.0032+0.02%19:58 EDT
Volume:3.44M
Turnover:44.60M
Market Cap:1.80B
PE:-3.85
High:13.49
Open:13.11
Low:12.68
Close:13.11
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.09
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.48
PE(LYR):-3.38

Loading ...

Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales But Fairer On Broader Checks

Simply Wall St.
·
Aug 06

Intellia Therapeutics Schedules Conference Call to Discuss Q2 2026 Results and Business Updates

Reuters
·
Jul 30

Intellia Therapeutics Cut to Underperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Jul 16

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 16

Movement Alert|Intellia Therapeutics Falls 9.74% in Regular Trading, Trading at $12.84

Market Focus
·
Jul 14

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed

Simply Wall St.
·
Jul 11

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

TIPRANKS
·
Jul 10

Intellia Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Jul 10

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating

MT Newswires Live
·
Jul 10

Intellia CFO Edward J. Dulac III Disposes of 4,677 Common Shares Valued at $84,186

Reuters
·
Jul 07

Intellia Grants 53,250 Inducement Rsus to 13 New Hires Under 2024 Plan

Reuters
·
Jul 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 07

Intellia Therapeutics rises 10.7%

TIPRANKS
·
Jun 17

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 17

Small U.S. Stocks End Mixed As Intellia Therapeutics Leads, Bandwidth Cl A Lags

Dow Jones
·
Jun 16

Intellia Therapeutics Shares Climb Following Positive Phase 3 Results

Dow Jones
·
Jun 16

Wedbush Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
Jun 15

Intellia says Phase 3 HAELO trial shows 87% attack reduction with lonvo-z in hereditary angioedema

Reuters
·
Jun 15

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

TIPRANKS
·
Jun 15